Medicare prescription drug plan sponsors don't want the government to take over the market any more than Big Pharma does. Can insurers and manufactuers work together to block interference in the new drug benefit?
Price controls are a threat to innovation. That has been the mantra of pharmaceutical companies in policy debates for a generation, though it hasn’t stopped some in Congress from advocating federal interventions in pricing.
But the refrain has been picked up in an unlikely quarter: by one of the largest pharmacy benefit management companies...
Create an account to read this article
Already a subscriber?
While the government announces eight to 15% cuts to the four products, industry groups urges for its operational improvement without expansion.
The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
While the government announces eight to 15% cuts to the four products, industry groups urges for its operational improvement without expansion.
Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.
Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.
